Halfway through 2026, OHE takes stock. We reflect on the defining moments of the year so far and look ahead to the policy shifts still to come. From US Most Favored Nation (MFN) pricing and its global ripple effects to rare disease access, the recent HEMA report publication and adopting broader value perspectives in HTA, and the new NICE threshold era. Join us for the analysis that helps you stay ahead.
Key takeaways
Speakers
Watch on-demand
Register to future webinars
Don’t miss what’s next, sign up to our newsletter for updates on future webinars and events.